Insulin-Like Growth Factor-1 and Anti-Vascular Endothelial Growth Factor in Retinopathy of Prematurity: Has the Time Come

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Neonatology

• Publication date

  2014-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1159/000365132PMID 25300950PMCID PMC4197141
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration: Two-Year Results.

  2020cited by this paper
• Intravitreal low‐dosage bevacizumab for retinopathy of prematurity

  2014cited by this paper
• Pharmakokinetik intravitreal applizierter VEGF-Inhibitoren

  2014cited by this paper
• Intravitreal bevacizumab for retinopathy of prematurity: refractive error results.

  2013cited by this paper
• What is the optimal dosage for intravitreal bevacizumab for retinopathy of prematurity?

  2013cited by this paper
• Oxygen Targets for Preterm Infants

  2013cited by this paper
• LONG-TERM EFFECT OF ANTIANGIOGENIC THERAPY FOR RETINOPATHY OF PREMATURITY Up to 5 Years of Follow-up

  2013cited by this paper
• Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial.

  2013cited by this paper
• Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedema

  2013cited by this paper
• Long-term Results of Lens-sparing Vitrectomy for Progressive Posterior-type Stage 4A Retinopathy of Prematurity

  2012cited by this paper
• Bevacizumab for retinopathy of prematurity.

  2012cited by this paper
• Serum concentrations of bevacizumab (avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity.

  2012cited by this paper
• Bevacizumab (Avastin) for retinopathy of prematurity: wrong dose, wrong drug, or both?

  2012cited by this paper
• Current role of cryotherapy in retinopathy of prematurity: a report by the American Academy of Ophthalmology.

  2012cited by this paper
• Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results.

  2012cited by this paper
• Current Role of Cryotherapy in Retinopathy of Prematurity: A Report by the American Academy of Ophthalmology

  2012cited by this paper
• Reactivation of retinopathy of prematurity after bevacizumab injection.

  2012cited by this paper
• Importance of early postnatal weight gain for normal retinal angiogenesis in very preterm infants: a multicenter study analyzing weight velocity deviations for the prediction of retinopathy of prematurity.

  2012cited by this paper
• Delayed onset atypical vitreoretinal traction band formation after an intravitreal injection of bevacizumab in stage 3 retinopathy of prematurity

  2012cited by this paper
• Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial.

  2012cited by this paper
• Neonatal bacteremia and retinopathy of prematurity: the ELGAN study.

  2011cited by this paper
• Effect of VEGF trap on normal retinal vascular development and oxygen-induced retinopathy in the dog.

  2011cited by this paper
• Ranibizumab and bevacizumab for neovascular age-related macular degeneration.

  2011cited by this paper
• INTRAOCULAR PHARMACOKINETICS AFTER A SINGLE INTRAVITREAL INJECTION OF 1.5 mg VERSUS 3.0 mg OF BEVACIZUMAB IN HUMANS

  2011cited by this paper
• Bevacizumab for retinopathy of prematurity.

  2011cited by this paper
• The association between stage 3 or higher retinopathy of prematurity and other disorders of prematurity.

  2011cited by this paper
• A Paradigm Shift in the Prevention of Retinopathy of Prematurity

  2011cited by this paper
• Bevacizumab for retinopathy of prematurity.

  2011cited by this paper
• On the use of antiangiogenetic medications for retinopathy of prematurity

  2011cited by this paper
• Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity.

  2011cited by this paper
• Outcome of eyes developing retinal detachment during the Early Treatment for Retinopathy of Prematurity study.

  2011cited by this paper
• Postnatal weight gain modifies severity and functional outcome of oxygen-induced proliferative retinopathy.

  2010cited by this paper
• High or Low Oxygen Saturation and Severe Retinopathy of Prematurity: A Meta-analysis

  2010cited by this paper
• New insights into the development of retinopathy of prematurity – importance of early weight gain

  2010cited by this paper
• TREATMENT OF TYPE 1 RETINOPATHY OF PREMATURITY WITH INTRAVITREAL BEVACIZUMAB (AVASTIN)

  2010cited by this paper
• Intravitreal bevacizumab in combination with laser therapy for the treatment of severe retinopathy of prematurity (ROP) associated with vitreous or retinal hemorrhage

  2010cited by this paper
• The mouse retina as an angiogenesis model.

  2010cited by this paper
• Plasma levels of vascular endothelial growth factor and pigment epithelium-derived factor before and after intravitreal injection of bevacizumab

  2010cited by this paper
• Longitudinal postnatal weight measurements for the prediction of retinopathy of prematurity.

  2010cited by this paper
• Weight gain measured at 6 weeks after birth as a predictor for severe retinopathy of prematurity: study with 317 very low birth weight preterm babies

  2009cited by this paper
• Validation of a new retinopathy of prematurity screening method monitoring longitudinal postnatal weight and insulinlike growth factor I.

  2009cited by this paper
• OFF-LABEL USE OF INTRAVITREAL BEVACIZUMAB (AVASTIN) FOR SALVAGE TREATMENT IN PROGRESSIVE THRESHOLD RETINOPATHY OF PREMATURITY

  2008cited by this paper
• Vitreous levels of stromal cell-derived factor 1 and vascular endothelial growth factor in patients with retinopathy of prematurity.

  2008cited by this paper
• Leitlinie zur augenärztlichen Screening-Untersuchung von Frühgeborenen - Arbeitsgruppe der Retinologischen Gesellschaft zur Erstellung der Leitlinie zur augenärztlichen Screening-Untersuchung von Frühgeborenen

  2008cited by this paper
• Longitudinal postnatal weight and insulin-like growth factor I measurements in the prediction of retinopathy of prematurity.

  2006cited by this paper
• The Role of Maternal Factors, Postnatal Nutrition, Weight Gain, and Gender in Regulation of Serum IGF-I among Preterm Infants

  2005cited by this paper
• [Retinopathy of prematurity].

  2004cited by this paper
• Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial.

  2004cited by this paper
• Postnatal serum insulin-like growth factor I deficiency is associated with retinopathy of prematurity and other complications of premature birth.

  2003influential reference
• Preliminary results of treatment of eyes with high-risk prethreshold retinopathy of prematurity in the early treatment for retinopathy of prematurity randomized trial.

  2003cited by this paper
• IGF-I is critical for normal vascularization of the human retina.

  2002cited by this paper
• Low IGF-I suppresses VEGF-survival signaling in retinal endothelial cells: Direct correlation with clinical retinopathy of prematurity

  2001cited by this paper
• Poor postnatal weight gain: a risk factor for severe retinopathy of prematurity.

  2000cited by this paper
• Systemic levels contribute significantly to increased intraocular IGF-I, IGF-II and IGF-BP3 [correction of IFG-BP3] in proliferative diabetic retinopathy.

  2000cited by this paper
• Vascularization of the human fetal retina: roles of vasculogenesis and angiogenesis.

  2000cited by this paper
• [Retinopathy of prematurity].

  1998cited by this paper
• Diode laser photocoagulation for prethreshold, posterior retinopathy of prematurity.

  1992cited by this paper
• Treatment of retinopathy of prematurity with argon laser photocoagulation.

  1992cited by this paper
• Laser photocoagulation for stage 3+ retinopathy of prematurity.

  1991cited by this paper
• Multicenter trial of cryotherapy for retinopathy of prematurity. Three-month outcome. Cryotherapy for Retinopathy of Prematurity Cooperative Group.

  1990cited by this paper
• Multicenter trial of cryotherapy for retinopathy of premadturity : three-month outcome

  1990cited by this paper
• Multicenter trial of cryotherapy for retinopathy of prematurity. One-year outcome--structure and function. Cryotherapy for Retinopathy of Prematurity Cooperative Group.

  1990cited by this paper
• Clinical Ophthalmology Dovepress Intraocular and Systemic Levels of Vascular Endothelial Growth Factor in Advanced Cases of Retinopathy of Prematurity

  year unknowncited by this paper

• Global Validation of the Postnatal Growth and Retinopathy of Prematurity Screening Model: A Systematic Review and Meta-analysis.

  2026cites this paper
• Early Nutritional Patterns and Metabolic Biomarkers Associated with ROP Severity

  2026cites this paper
• Breastfeeding and Future Cardiovascular, Kidney, and Metabolic Health—A Narrative Review

  2025cites this paper
• SIRT2 inhibition attenuates the vasculopathy and vision impairment via Akt signaling in retinopathy of prematurity.

  2023cites this paper
• Latest Trends in Retinopathy of Prematurity: Research on Risk Factors, Diagnostic Methods and Therapies

  2023cites this paper
• The Role of Insulin-like Growth Factor-1 and Its Receptor in the Eye: A Review and Implications for IGF-1R Inhibition

  2022cites this paper
• The Serum Levels of Asymmetric Dimethylarginine, Vascular Endothelial Growth Factor, and Insulin-Like Growth Factor-1 in Preterms with Retinopathy of Prematurity

  2021cites this paper
• The Alexandria retinopathy of prematurity model (Alex-ROP): postnatal weight gain screening algorithm application in a developing country.

  2019cites this paper
• A Pathogenic Relationship of Bronchopulmonary Dysplasia and Retinopathy of Prematurity? A Review of Angiogenic Mediators in Both Diseases

  2018cites this paper
• Enteral Arg-Gln Dipeptide Administration Increases Retinal Docosahexaenoic Acid and Neuroprotectin D1 in a Murine Model of Retinopathy of Prematurity

  2018cites this paper
• Asymmetric Outcomes of Type 1 Retinopathy of Prematurity after Bilateral Intravitreal Ranibizumab Treatment

  2017cites this paper
• Retinal vasculature development in health and disease

  2017cites this paper
• Visual outcome and refractive status in first 3 years of age in preterm infants suffered from laser-treated Type 1 retinopathy of prematurity (ROP): a 6-year retrospective review in a tertiary centre in Hong Kong

  2017cites this paper
• Retinopathy of Prematurity Is Associated with Increased Systolic Blood Pressure in Adults Who Were Born Preterm

  2017cites this paper
• The role of serial measurements of serum insulin-like growth factor 1 levels in the development of retinopathy of prematurity.

  2017cites this paper
• Insulin-like Growth Factor I ( IGF-I ) as a Predictive Factor of Retinopathy of Prematurity

  2017cites this paper
• Follow-up to Age 4 Years of Treatment of Type 1 Retinopathy of Prematurity Intravitreal Bevacizumab Injection versus Laser: Fluorescein Angiographic Findings.

  2017cites this paper
• Up‐regulated basigin‐2 in microglia induced by hypoxia promotes retinal angiogenesis

  2017cites this paper
• Systemic Inflammation-Associated Proteins and Retinopathy of Prematurity in Infants Born Before the 28th Week of Gestation

  2017cites this paper
• Downregulation of Insulin-Like Growth Factor-1 via Nitric Oxide Production in a Hypergalactosemic Model of Neonate Skin Fibroblast Cultures

  2016cites this paper
• The Specificity of the WINROP Algorithm Can Be Significantly Increased by Reassessment of the WINROP Alarm

  2015cites this paper
• Intravitreal anti-VEGF therapy as a treatment for retinopathy of prematurity: what we know after 7 years.

  2015cites this paper